Bladder Cancer

>

Latest News

Nivolumab plus ipilimumab has shown a response benefit when given at an increased dose for those with metastatic urothelial carcinoma.
Nivolumab/Ipilimumab Shows Improved Benefit in Urothelial Carcinoma

May 22nd 2024

Nivolumab plus ipilimumab has shown a response benefit when given at an increased dose for those with metastatic urothelial carcinoma.

Expert Commentary on the Product Profile of Enfortumab Vedotin Plus Pembrolizumab
Expert Commentary on the Product Profile of Enfortumab Vedotin Plus Pembrolizumab

May 20th 2024

Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.
Nivolumab Combo Shows Efficacy, Safety in Muscle-Invasive Bladder Cancer

May 10th 2024

Findings from the CheckMate-901 study support the use of frontline nivolumab plus gemcitabine/cisplatin in advanced urothelial carcinoma.
Nivolumab Combo Significantly Boosts Survival in Urothelial Carcinoma

May 8th 2024

All patients with a response to TAR-200 did not have progression to muscle-invasive bladder cancer or metastatic disease in the SunRISe-1 trial.
Lasting Responses Observed With TAR-200 in BCG-Unresponsive NMIBC

May 7th 2024

Video Series
Video Interviews
Podcasts
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

More News